User menu

Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family

Bibliographic reference Wang, Xiao-Fei ; Cohen, William M. ; Castelli, Florence A. ; Almunia, Christine ; Lethe, Bernard ; et. al. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. In: Cancer Immunology Immunotherapy, Vol. 56, no. 6, p. 807-818 (2007)
Permanent URL
  1. Atanackovic D., Altorki N. K., Stockert E., Williamson B., Jungbluth A. A., Ritter E., Santiago D., Ferrara C. A., Matsuo M., Selvakumar A., Dupont B., Chen Y.-T., Hoffman E. W., Ritter G., Old L. J., Gnjatic S., Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients, 10.4049/jimmunol.172.5.3289
  2. Buhot C, Chenal A, Sanson A, Pouvelle-Moratille S, Gelb MH, Menez A, Gillet D, Maillere B (2004) Alteration of the tertiary structure of the major bee venom allergen Api m 1 by multiple mutations is concomitant with low IgE reactivity. Protein Sci 13:2970–2978
  3. Castelli F. A., Buhot C., Sanson A., Zarour H., Pouvelle-Moratille S., Nonn C., Gahery-Segard H., Guillet J.-G., Menez A., Georges B., Maillere B., HLA-DP4, the Most Frequent HLA II Molecule, Defines a New Supertype of Peptide-Binding Specificity, 10.4049/jimmunol.169.12.6928
  4. Charron D, Fauchet R, Albert E, Bodmer J, Cambon-Thomsen A, Degos L, Hors J, Piazza A, Schreuder I (1997) (eds) Genetic diversity of HLA, functional and medical implication. In: Twelfth international histocompatibility workshop and conference, Charron D Paris, France
  5. Chaux P, Lethe B, Van Snick J, Corthals J, Schultz ES, Cambiaso CL, Boon T, van der Bruggen P (2001) A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells. Eur J Immunol 31:1910–1916
  6. Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P (1999) Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol 163:2928–2936
  7. Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P (1998) Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int J Cancer 77:538–542
  8. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P (1999) Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189:767–778
  9. Cibotti R, Cabaniols JP, Pannetier C, Delarbre C, Vergnon I, Kanellopoulos JM, Kourilsky P (1994) Public and private V beta T cell receptor repertoires against hen egg white lysozyme (HEL) in nontransgenic versus HEL transgenic mice. J Exp Med 180:861–872
  10. Cohen W. M., Pouvelle-Moratille S., Wang X.-F., Farci S., Munier G., Charron D., Menez A., Busson M., Maillere B., Scanning the HIV Genome for CD4+ T Cell Epitopes Restricted to HLA-DP4, the Most Prevalent HLA Class II Molecule, 10.4049/jimmunol.176.9.5401
  11. Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J, Conti-Fine BM, Rugarli C, Traversari C, Protti MP (2003) Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood 101:1038–1044
  12. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T (2001) A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 98:10290–10295
  13. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C et al (1994) Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40:360–369
  14. Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, Scholz S, Santantonio T, Houghton M, Southwood S, Sette A, Pape GR (1997) Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71:6011–6019
  15. Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, Van Pel A (1999) Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J Immunol 162:6849–6854
  16. Kobayashi H, Song Y, Hoon DS, Appella E, Celis E (2001) Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 61:4773–4778
  17. Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T (2004) Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 101(Suppl 2):14631–14638
  18. Mandic M., Castelli F., Janjic B., Almunia C., Andrade P., Gillet D., Brusic V., Kirkwood J. M., Maillere B., Zarour H. M., One NY-ESO-1-Derived Epitope That Promiscuously Binds to Multiple HLA-DR and HLA-DP4 Molecules and Stimulates Autologous CD4+ T Cells from Patients with NY-ESO-1-Expressing Melanoma, 10.4049/jimmunol.174.3.1751
  19. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219–230
  20. Panelli M. C., Bettinotti M. P., Lally K., Ohnmacht G. A., Li Y., Robbins P., Riker A., Rosenberg S. A., Marincola F. M., A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12, 10.4049/jimmunol.164.8.4382
  21. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915
  22. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279–1288
  23. Schultz ES, Lethe B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P (2000) A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 60:6272–6275
  24. Schultz E. S., Schuler-Thurner B., Stroobant V., Jenne L., Berger T. G., Thielemanns K., van der Bruggen P., Schuler G., Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy, 10.4049/jimmunol.172.2.1304
  25. Serrano A, Lethe B, Delroisse JM, Lurquin C, De Plaen E, Brasseur F, Rimoldi D, Boon T (1999) Quantitative evaluation of the expression of MAGE genes in tumors by limiting dilution of cDNA libraries. Int J Cancer 83:664–669
  26. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160:3363–3373
  27. Tangri S., Mothe B. R., Eisenbraun J., Sidney J., Southwood S., Briggs K., Zinckgraf J., Bilsel P., Newman M., Chesnut R., LiCalsi C., Sette A., Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity, 10.4049/jimmunol.174.6.3187
  28. Texier C, Hervé M, Pouvelle S, Ménez A, Maillere B (1999) On the diversity and heterogeneity of H-2d restricted determinants and T cell epitopes from the major bee venom allergen. Int Immunol 11:1313–1325
  29. Texier C, Pouvelle-Moratille S, Buhot C, Castelli FA, Pecquet C, Menez A, Leynadier F, Maillere B (2002) Emerging principles for the design of promiscuous HLA-DR-restricted peptides: an example from the major bee venom allergen. Eur J Immunol 32:3699–3707
  30. Valmori D, Souleimanian NE, Hesdorffer CS, Old LJ, Ayyoub M (2005) Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4(+) T cells in cancer-free individuals. Clin Immunol 117:161–167
  31. Van den Eynde BJ, van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9:684–693
  32. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647
  33. Visseren MJ, van der Burg SH, van der Voort EI, Brandt RM, Schrier PI, van der Bruggen P, Boon T, Melief CJ, Kast WM (1997) Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int J Cancer 73:125–130
  34. Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF (2004) Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20:107–118
  35. Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, Sidney J, Sette A, Storkus WJ (2000) Melan-A/MART-1(51–73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci USA 97:400–405
  36. Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM (2002) NY-ESO-1 119–143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res 62:213–218
  37. Zeng G, Li Y, El-Gamil M, Sidney J, Sette A, Wang RF, Rosenberg SA, Robbins PF (2002) Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 62:3630–3635
  38. Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF (2001) CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA 98:3964–3969
  39. Zhang Y., Chaux P., Stroobant V., Eggermont A. M. M., Corthals J., Maillere B., Thielemans K., Marchand M., Boon T., van der Bruggen P., A MAGE-3 Peptide Presented by HLA-DR1 to CD4+ T Cells That Were Isolated from a Melanoma Patient Vaccinated with a MAGE-3 Protein, 10.4049/jimmunol.171.1.219
  40. Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D (2005) A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Eur J Immunol 35:1066–1075
  41. Zhang Y., Sun Z., Nicolay H., Meyer R. G., Renkvist N., Stroobant V., Corthals J., Carrasco J., Eggermont A. M. M., Marchand M., Thielemans K., Wolfel T., Boon T., van der Bruggen P., Monitoring of Anti-Vaccine CD4 T Cell Frequencies in Melanoma Patients Vaccinated with a MAGE-3 Protein, 10.4049/jimmunol.174.4.2404